December 2015
Corporate HQ
Nottingham, UK

Quotient is a drug development market innovator with a ‘one of a kind’ proposition offering integrated CDMO and CRO, known as Translation Pharmaceutics and represents an investment in a high growth market leader with a unique service.

Transformed from a local UK market leader for Phase I trials into a global pharma full lifecycle drug development service provider.

Value Creation Summary

Enablement & Alignment

Creation of a scaled transatlantic platform offering Translational Pharmaceutics® to better serve innovator clients in both the US and EU.

Primary focus on science and service led approach with maintenance of quality standards coming first and foremost.

Capability & Capacity

Greenfield development of additional capacity to support commercial scale manufacturing capacity in order to capture lifetime value of a molecule.

Upgrades to the Finance, IT, HR, and procurement functions as well as senior management additions facilitated the addition of 580 (majority highly skilled) employees over the period.

Building Strategic Footprints

Completion of four bolt-on acquisitions to deliver a transformational Transatlantic footprint, expanding from clinical batch into commercial batch manufacturing, adding significant new capacity to facilitate growth and bringing new service capabilities for niche, difficult to manufacture products

A differentiated service capability with a significant global presence

Following the acquisitions of Co-formulate, Pharmaterials, QS Pharma and SeaView.